Skip to content

Sangamo Therapeutics, Inc

SGMOQ· OTCCore metricsCIK 1001233

Biological products, except diagnostic substances175 peers

Close
Oct 23, 2026 · +0.00%
Market cap
$49.71M
414.29M shares
Filings
1,019
$1.44M
Q1 2026−31.6% FY25 yoy
-$31.00M
Q1 2026N/M FY25 yoy
-$31.95M
Q1 2026N/M FY25 yoy
-$19.30M
Q1 2026derivedN/M FY25 yoy
-$0.08
Q1 2026N/M FY25 yoy
$27.59M
Q1 2026−50.0% FY25 yoy
$49.71M
—
1.4×
—
-181.95%
—

Twelve months to Mar 31, 2026 · derived

Price

$0.1281.77%$0.5384past year
Oct 23, 2026 · Official close
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$39.55MFY 2025
$176.23M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$39,552,000reported
FY 20242024-12-31$57,800,000reported
FY 20232023-12-31$176,232,000reported
FY 20222022-12-31$111,299,000reported
FY 20212021-12-31$110,701,000reported
FY 20202020-12-31$118,192,000reported
FY 20192019-12-31$102,428,000reported
FY 20182018-12-31$84,452,000reported
FY 20172017-12-31$36,567,000reported
FY 20162016-12-31$19,389,000reported
FY 20152015-12-31$39,539,000reported
FY 20142014-12-31$45,870,000reported

Biological products, except diagnostic substances

Sangamo Therapeutics, Inc is the 48th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Sangamo Therapeutics, Inc · CIK 1001233 · Engraved from SEC EDGAR